Drug intelligence / Profile preview

rituximab + idelalisib + venetoclax

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Triple combination therapy consisting of the anti-CD20 monoclonal antibody rituximab, the PI3K delta inhibitor idelalisib, and the BCL-2 inhibitor venetoclax. It is being evaluated in the Phase 1 RIVe-CLL/SLL trial (NCT03639324) led by Virginia Commonwealth University for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Dose combination 1-3 specifically refers to a regimen of 100 mg BID of idelalisib and 200 mg QD of venetoclax, administered following a lead-in period with idelalisib and rituximab. The combination aims to achieve deeper clinical responses by targeting multiple survival pathways in B-cell malignancies.

Other names: rituximab + idelalisib + venetoclax combination

Targets

PIK3CD (Phosphatidylinositol 3-kinase delta)BCL-2 (BCL-2 family)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on rituximab + idelalisib + venetoclax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rituximab + idelalisib + venetoclax.

Explore the full profile